Elevated soluble ST2 predicts atrial fibrillation development and recurrence after catheter ablation in 14,582 participants.

This systematic review and meta-analysis synthesized data from 19 studies encompassing a total of 14,582 participants to evaluate the role of soluble ST2 (sST2) in atrial fibrillation (AF). The study population included individuals with AF, those with sinus rhythm, and patients experiencing recurrent AF. The specific setting of the original studies was not reported in the source data. The primary exposure was circulating sST2 levels, which were compared against sinus rhythm states and lower sST2 levels to assess associations with AF development and recurrence after catheter ablation. The analysis aimed to determine if sST2 serves as a biomarker for disease progression and treatment failure.

Regarding the primary outcome of AF development versus sinus rhythm, the meta-analysis found that sST2 levels were significantly greater in individuals with AF compared to those with sinus rhythm. The standardized mean difference (SMD) was 0.45, with a 95% confidence interval ranging from 0.29 to 0.61 and a p-value less than 0.01. This indicates a consistent elevation of the biomarker in the presence of the arrhythmia. Furthermore, when assessing the likelihood of developing AF, elevated sST2 levels were correlated with an increased risk. The hazard ratio (HR) was 1.07, with a 95% confidence interval of 1.00 to 1.14 and a p-value of 0.04, suggesting a statistically significant association between higher biomarker levels and incident AF.

In patients undergoing catheter ablation, the analysis focused on the risk of recurrent AF. Individuals with recurrent AF demonstrated significantly higher sST2 levels compared to those without recurrence. The SMD for this comparison was 0.78, with a 95% confidence interval of 0.32 to 1.23 and a p-value less than 0.01. Additionally, an elevated level of sST2 was related to a greater risk of recurrent AF after a successful procedure. The hazard ratio for this outcome was 1.17, with a 95% confidence interval of 1.04 to 1.32 and a p-value of 0.01. These results collectively position sST2 as a significant predictor for recurrent AF following ablation therapy.

The study did not report specific secondary outcomes beyond the primary endpoints of AF development and recurrence. Consequently, no additional efficacy or stratification data were available for analysis. Safety and tolerability findings were not reported in the included studies; therefore, adverse event rates, serious adverse events, discontinuations, and overall tolerability profiles regarding sST2 measurement or its clinical implications could not be evaluated. The absence of this data limits the assessment of potential harms associated with using sST2 in clinical workflows.

The practice relevance of these findings is that sST2 appears to be a significant predictor for recurrent AF after a successful catheter ablation procedure. However, the study design precludes definitive causal conclusions. The authors noted that causality was not reported, and the certainty of the evidence was not explicitly graded in the provided data. While the statistical associations are robust, the observational nature of the underlying studies means that sST2 elevation may be a consequence of AF pathophysiology rather than a direct driver of recurrence.

Several methodological limitations must be considered when interpreting these results. The specific settings of the 19 included studies were not reported, which may introduce heterogeneity regarding patient demographics, comorbidities, and ablation techniques. The lack of reported safety data and the absence of a formal certainty assessment further constrain the applicability of these findings to routine clinical decision-making. Additionally, absolute numbers for outcomes were not reported, limiting the calculation of absolute risk differences. These gaps suggest that while sST2 is a promising biomarker, its utility requires validation in prospective trials with standardized protocols.

Clinically, these results suggest that measuring sST2 could potentially help identify patients at higher risk for AF recurrence, although current evidence does not support its use for guiding treatment decisions. The question remains whether targeting the sST2 pathway could prevent recurrence or if the biomarker simply reflects underlying inflammation and fibrosis. Further research is needed to establish causality, define optimal cutoff values for risk stratification, and determine if sST2-guided therapies improve patient outcomes compared to standard of care.

In summary, this meta-analysis provides evidence that elevated sST2 levels are associated with both the development of AF and its recurrence after catheter ablation. The hazard ratios and standardized mean differences indicate a meaningful association, yet the observational design prevents causal inference. Clinicians should interpret these findings as indicative of a strong correlation rather than a proven mechanism for disease progression. Until prospective studies confirm the utility of sST2 in guiding management, it remains a biomarker of interest rather than a standard clinical tool.

Key unanswered questions include whether sST2 levels can predict recurrence before ablation, if serial measurements improve prognostic accuracy, and whether interventions targeting sST2 reduce AF burden. The lack of reported funding sources and conflicts of interest also warrants caution, as industry sponsorship could influence study selection or interpretation. Ultimately, while sST2 shows promise, its integration into clinical practice awaits further high-quality evidence.